Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia
Stephan Stilgenbauer(Universität Ulm), John F. Seymour(The Royal Melbourne Hospital), Sebastian Böttcher(University Hospital Schleswig-Holstein), Wendy Sinai(AbbVie (United States)), Eugen Tausch(Universität Ulm), Peter Hillmen(University of Leeds), Andrew W. Roberts(The Royal Melbourne Hospital), Relja Popovic(Loyola University Medical Center), Nabanita Mukherjee(AbbVie (United States)), Matthew S. Davids(Dana-Farber Cancer Institute), Arnon P. Kater(Amsterdam University Medical Centers), Brenda Chyla(AbbVie (United States)), Michael Moran(AbbVie (United States)), Michael Hallek(Integrated Oncology (United States)), Michelle Boyer(Amgen (United States)), Christof Schneider(Universität Ulm), Majd T. Ghanim(AbbVie (United States)), Barbara Eichhorst(University of Cologne), William G. Wierda(University of Maryland, Baltimore), Johannes Schetelig(University Hospital Carl Gustav Carus), Xifeng Wang(University of North Carolina at Chapel Hill), Yanwen Jiang
Cited by 13
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k